InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

However, the effect of cataract surgery on other measures of dry eye is unclear, with inconsistent outcomes across studies. Researchers conducted a systematic review of 20 observational studies ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease. Under the terms of the option ...

After hours: January 17 at 6:47:44 PM EST Loading Chart for BLCO ...

Continuous Glucose Monitor Data Predicts Type 1 Diabetes Complications Jan. 15, 2025 — Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes ...